Playback speed
10 seconds
ASH 2022 Primary Results of STIMULUS-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition With Sabatolimab Added to HMAs in Adult Patients With Higher-Risk MDS
By
ASH 2022 Conference Coverage
FEATURING
Amer Zeidan
By
ASH 2022 Conference Coverage
FEATURING
Amer Zeidan
122 views
December 21, 2022
Login to view comments.
Click here to Login